WallStSmart

Alignment Healthcare LLC (ALHC)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1388% more annual revenue ($58.74B vs $3.95B). AZN leads profitability with a 17.4% profit margin vs -0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).

ALHC

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 6.8
Piotroski: 5/9Altman Z: 3.87

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALHCUndervalued (+63.3%)

Margin of Safety

+63.3%

Fair Value

$55.62

Current Price

$22.54

$33.08 discount

UndervaluedFair: $55.62Overvalued
AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALHC2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.4%10/10

Revenue surging 44.4% year-over-year

Altman Z-ScoreHealth
3.8710/10

Safe zone — low bankruptcy risk

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

ALHC4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
25.6x2/10

Trading at 25.6x book value

Return on EquityProfitability
-0.7%2/10

ROE of -0.7% — below average capital efficiency

Free Cash FlowQuality
$-66.63M2/10

Negative free cash flow — burning cash

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ALHC

The strongest argument for ALHC centers on Revenue Growth, Altman Z-Score. Revenue growth of 44.4% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : ALHC

The primary concerns for ALHC are EPS Growth, Price/Book, Return on Equity.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

ALHC profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.

ALHC carries more volatility with a beta of 1.20 — expect wider price swings.

ALHC is growing revenue faster at 44.4% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 37/100), backed by strong 17.4% margins. ALHC offers better value entry with a 63.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alignment Healthcare LLC

HEALTHCARE · HEALTHCARE PLANS · USA

Alignment Healthcare, Inc. provides a consumer-centric platform that provides personalized healthcare to seniors in the United States. The company is headquartered in Orange, California.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?